Elliott Richelson, MD: The Clinical Relevance of Antidepressant Interaction With Neurotransmitter Transporters and Receptors

Name: Elliott Richelson, MD: The Clinical Relevance of Antidepressant Interaction With Neurotransmitter Transporters and Receptors
SKU: 3067
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 36 No. 4 Articles Tags: acetylcholine, dopamine, elliott-richelson, histamine, norepinephrine, serotonin

Description

Elliott Richelson, MD: The Clinical Relevance of Antidepressant Interaction With Neurotransmitter Transporters and Receptors

Description

Elliott Richelson, MD

GENERAL PSYCHOPHARMACOLOGY

The Clinical Relevance of Antidepressant Interaction With Neurotransmitter Transporters and Receptors

Elliott Richelson, MD

Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia

OPEN ACCESS: Serotonergic Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Review of Past Development, Pitfalls and Failures, and a Look to the Future

Paolo Castrogiovanni, MD: Can Serotonin and Fluoxetine Levels in Plasma and Platelets Predict Clinical Response in Depression?

Depression Treatment: A Lifelong Commitment?

Elliott Richelson, MD: The Clinical Relevance of Antidepressant Interaction With Neurotransmitter Transporters and Receptors

Description

Elliott Richelson, MD

GENERAL PSYCHOPHARMACOLOGY

The Clinical Relevance of Antidepressant Interaction With Neurotransmitter Transporters and Receptors

Elliott Richelson, MD

Related products

Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia

OPEN ACCESS: Serotonergic Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Review of Past Development, Pitfalls and Failures, and a Look to the Future

Paolo Castrogiovanni, MD: Can Serotonin and Fluoxetine Levels in Plasma and Platelets Predict Clinical Response in Depression?

Depression Treatment: A Lifelong Commitment?